Overview

To Demonstrate the Relative Bioavailability of Divalproex Sodium 500 mg Delayed Release Tablets Under Fed Conditions

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
0
Participant gender:
Male
Summary
To demonstrate the relative bioavailability of Divalproex Sodium 500 mg delayed release tablets under fed conditions.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Sandoz
Treatments:
Valproic Acid
Criteria
Inclusion Criteria:

- No clinically significant abnormal finding on physical exam, medical history, or
clinical laboratory results on screening.

Exclusion Criteria:

- Positive test results for HIV or hepatitis B or C.

- Treatment for drug or alcohol dependence.